{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:51:42Z","timestamp":1772808702833,"version":"3.50.1"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The COVID-19 pandemic has pushed healthcare systems globally to a breaking point. The urgent need for effective and affordable COVID-19 treatments calls for repurposing combinations of approved drugs. The challenge is to identify which combinations are likely to be most effective and at what stages of the disease. Here, we present the first disease-stage executable signalling network model of SARS-CoV-2-host interactions used to predict effective repurposed drug combinations for treating early- and late stage severe disease. Using our executable model, we performed in silico screening of 9870 pairs of 140 potential targets and have identified nine new drug combinations. Camostat and Apilimod were predicted to be the most promising combination in effectively supressing viral replication in the early stages of severe disease and were validated experimentally in human Caco-2 cells. Our study further demonstrates the power of executable mechanistic modelling to enable rapid pre-clinical evaluation of combination therapies tailored to disease progression. It also presents a novel resource and expandable model system that can respond to further needs in the pandemic.<\/jats:p>","DOI":"10.1038\/s41746-022-00561-5","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T06:16:32Z","timestamp":1644819392000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Executable network of SARS-CoV-2-host interaction predicts drug combination treatments"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2479-180X","authenticated-orcid":false,"given":"Rowan","family":"Howell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Kathrin","family":"Reuschl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Abbott-Imboden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mervyn","family":"Singer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6102-2375","authenticated-orcid":false,"given":"David M.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare L.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Chain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"Jolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4477-9047","authenticated-orcid":false,"given":"Jasmin","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"561_CR1","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.chom.2020.05.008","volume":"27","author":"A Park","year":"2020","unstructured":"Park, A. & Iwasaki, A. Type I and Type III interferons \u2013 Induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe 27, 870\u2013878 (2020).","journal-title":"Cell Host Microbe"},{"key":"561_CR2","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S1474-4422(20)30221-0","volume":"19","author":"MA Ellul","year":"2020","unstructured":"Ellul, M. A. et al. Neurological associations of COVID-19. Lancet Neurol. 19, 767\u2013783 (2020).","journal-title":"Lancet Neurol."},{"key":"561_CR3","doi-asserted-by":"publisher","first-page":"e276","DOI":"10.1016\/S1473-3099(20)30651-4","volume":"20","author":"L Jiang","year":"2020","unstructured":"Jiang, L. et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect. Dis. 20, e276\u2013e288 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"561_CR4","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1182\/blood.2020006000","volume":"135","author":"JM Connors","year":"2020","unstructured":"Connors, J. M. & Levy, J. H. COVID-19 and its implications for thrombosis and anticoagulation. Blood 135, 2033\u20132040 (2020).","journal-title":"Blood"},{"key":"561_CR5","unstructured":"Estimated Disease Burden of COVID-19 | CDC. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/cases-updates\/burden.html."},{"key":"561_CR6","doi-asserted-by":"publisher","first-page":"e1010","DOI":"10.1093\/cid\/ciaa1780","volume":"72","author":"H Reese","year":"2021","unstructured":"Reese, H. et al. Estimated incidence of coronavirus disease 2019 (COVID-19) illness and hospitalization\u2014United States, February\u2013September 2020. Clin. Infect. Dis. 72, e1010\u2013e1017 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"561_CR7","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1016\/j.cell.2021.02.018","volume":"184","author":"C Liu","year":"2021","unstructured":"Liu, C. et al. Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19. Cell 184, 1836\u20131857.e22 (2021).","journal-title":"Cell"},{"key":"561_CR8","doi-asserted-by":"publisher","first-page":"e20210583","DOI":"10.1084\/jem.20210583","volume":"218","author":"NR Cheemarla","year":"2021","unstructured":"Cheemarla, N. R. et al. Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics. J. Exp. Med. 218, e20210583 (2021).","journal-title":"J. Exp. Med."},{"key":"561_CR9","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-020-2588-y","volume":"584","author":"C Lucas","year":"2020","unstructured":"Lucas, C. et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584, 463\u2013469 (2020).","journal-title":"Nature"},{"key":"561_CR10","doi-asserted-by":"publisher","first-page":"eabd4570","DOI":"10.1126\/science.abd4570","volume":"370","author":"Q Zhang","year":"2020","unstructured":"Zhang, Q. et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370, eabd4570 (2020).","journal-title":"Science"},{"key":"561_CR11","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1038\/s41591-020-1038-6","volume":"26","author":"AG Laing","year":"2020","unstructured":"Laing, A. G. et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat. Med. 26, 1623\u20131635 (2020).","journal-title":"Nat. Med."},{"key":"561_CR12","doi-asserted-by":"publisher","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","volume":"370","author":"P Bastard","year":"2020","unstructured":"Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585 (2020).","journal-title":"Science"},{"key":"561_CR13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41586-020-03065-y","volume":"591","author":"E Pairo-Castineira","year":"2021","unstructured":"Pairo-Castineira, E. et al. Genetic mechanisms of critical illness in COVID-19. Nature 591, 92\u201398 (2021).","journal-title":"Nature"},{"key":"561_CR14","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41586-021-03234-7","volume":"591","author":"AJ Combes","year":"2021","unstructured":"Combes, A. J. et al. Global absence and targeting of protective immune states in severe COVID-19. Nature 591, 124\u2013130 (2021).","journal-title":"Nature"},{"key":"561_CR15","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1126\/science.abc6027","volume":"369","author":"J Hadjadj","year":"2020","unstructured":"Hadjadj, J. et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 369, 718\u2013724 (2020).","journal-title":"Science"},{"key":"561_CR16","doi-asserted-by":"publisher","unstructured":"Thorne, L. G. et al. Evolution of enhanced innate immune evasion by SARS-CoV-2. Nature. https:\/\/doi.org\/10.1038\/s41586-021-04352-y (2021).","DOI":"10.1038\/s41586-021-04352-y"},{"key":"561_CR17","doi-asserted-by":"publisher","first-page":"e107826","DOI":"10.15252\/embj.2021107826","volume":"40","author":"LG Thorne","year":"2021","unstructured":"Thorne, L. G. et al. SARS-CoV-2 sensing by RIG-I and MDA5 links epithelial infection to macrophage inflammation. EMBO J. 40, e107826 (2021).","journal-title":"EMBO J."},{"key":"561_CR18","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.gendis.2020.06.009","volume":"7","author":"S-H Lin","year":"2020","unstructured":"Lin, S.-H., Zhao, Y.-S., Zhou, D.-X., Zhou, F.-C. & Xu, F. Coronavirus disease 2019 (COVID-19): cytokine storms, hyperinflammatory phenotypes, and acute respiratory distress syndrome. Genes Dis. 7, 520\u2013527 (2020).","journal-title":"Genes Dis"},{"key":"561_CR19","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/1475-5890.12227","volume":"41","author":"C Propper","year":"2020","unstructured":"Propper, C., Stoye, G. & Zaranko, B. The wider impacts of the coronavirus pandemic on the NHS. Fisc. Stud. 41, 345\u2013356 (2020).","journal-title":"Fisc. Stud."},{"key":"561_CR20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1093\/occmed\/kqaa220","volume":"71","author":"N Greenberg","year":"2021","unstructured":"Greenberg, N. et al. Mental health of staff working in intensive care during Covid-19. Occup. Med. 71, 62\u201367 (2021).","journal-title":"Occup. Med."},{"key":"561_CR21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99\u2013111 (2021).","journal-title":"Lancet"},{"key":"561_CR22","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"561_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"561_CR24","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/S0140-6736(20)32318-7","volume":"396","author":"RM Anderson","year":"2020","unstructured":"Anderson, R. M., Vegvari, C., Truscott, J. & Collyer, B. S. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. Lancet 396, 1614\u20131616 (2020).","journal-title":"Lancet"},{"key":"561_CR25","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","volume":"20","author":"M Jeyanathan","year":"2020","unstructured":"Jeyanathan, M. et al. Immunological considerations for COVID-19 vaccine strategies. Nat. Rev. Immunol. 20, 615\u2013632 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"561_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s43588-020-00007-6","volume":"1","author":"G Galindez","year":"2021","unstructured":"Galindez, G. et al. Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies. Nat. Comput. Sci. 1, 33\u201341 (2021).","journal-title":"Nat. Comput. Sci."},{"key":"561_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/srep08190","volume":"5","author":"R Chuang","year":"2015","unstructured":"Chuang, R. et al. Drug target optimization in chronic myeloid leukemia using innovative computational platform. Sci. Rep. 5, 8190 (2015).","journal-title":"Sci. Rep."},{"key":"561_CR28","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/0008-5472.CAN-16-1578","volume":"77","author":"D Silverbush","year":"2017","unstructured":"Silverbush, D. et al. Cell-specific computational modeling of the PIM pathway in acute myeloid leukemia. Cancer Res. 77, 827\u2013838 (2017).","journal-title":"Cancer Res."},{"key":"561_CR29","doi-asserted-by":"publisher","first-page":"22399","DOI":"10.1073\/pnas.1903485116","volume":"116","author":"P Kreuzaler","year":"2019","unstructured":"Kreuzaler, P. et al. Heterogeneity of Myc expression in breast cancer exposes pharmacological vulnerabilities revealed through executable mechanistic modeling. Proc. Natl Acad. Sci. USA 116, 22399\u201322408 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"561_CR30","first-page":"54","volume":"6","author":"MA Clarke","year":"2020","unstructured":"Clarke, M. A. & Fisher, J. Executable cancer models: successes and challenges. Nat. Rev. Cancer 6, 54\u201360 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"561_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd.2017.162","volume":"17","author":"SHE Kaufmann","year":"2018","unstructured":"Kaufmann, S. H. E., Dorhoi, A., Hotchkiss, R. S. & Bartenschlager, R. Host-directed therapies for bacterial and viral infections. Nat. Rev. Drug Discov. 17, 35\u201356 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"561_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1752-0509-1-4","volume":"1","author":"MA Schaub","year":"2007","unstructured":"Schaub, M. A., Henzinger, T. A. & Fisher, J. Qualitative networks: a symbolic approach to analyze biological signaling networks. BMC Syst. Biol. 1, 4 (2007).","journal-title":"BMC Syst. Biol."},{"key":"561_CR33","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1126\/science.abc6261","volume":"369","author":"PS Arunachalam","year":"2020","unstructured":"Arunachalam, P. S. et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science 369, 1210\u20131220 (2020).","journal-title":"Science"},{"key":"561_CR34","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1126\/science.abc3545","volume":"369","author":"A Broggi","year":"2020","unstructured":"Broggi, A. et al. Type III interferons disrupt the lung epithelial barrier upon viral recognition. Science 369, 706\u2013712 (2020).","journal-title":"Science"},{"key":"561_CR35","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel, J. H. et al. Remdesivir for the treatment of covid-19 \u2014 Final report. N. Engl. J. Med. 383, 1813\u20131826 (2020).","journal-title":"N. Engl. J. Med."},{"key":"561_CR36","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao, B. et al. A trial of lopinavir\u2013ritonavir in adults hospitalized with severe covid-19. N. Engl. J. Med. 382, 1787\u20131799 (2020).","journal-title":"N. Engl. J. Med."},{"key":"561_CR37","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"RECOVERY Collaborative Group.","year":"2021","unstructured":"RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397, 1637\u20131645 (2021).","journal-title":"Lancet"},{"key":"561_CR38","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"The RECOVERY Collaborative Group.","year":"2021","unstructured":"The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with covid-19. N. Engl. J. Med. 384, 693\u2013704 (2021).","journal-title":"N. Engl. J. Med."},{"key":"561_CR39","unstructured":"ClinicalTrials.gov. US National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04293887 (2020)."},{"key":"561_CR40","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaci.2020.05.019","volume":"146","author":"Y Cao","year":"2020","unstructured":"Cao, Y. et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. J. Allergy Clin. Immunol. 146, 137\u2013146.e3 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"561_CR41","doi-asserted-by":"publisher","first-page":"104786","DOI":"10.1016\/j.antiviral.2020.104786","volume":"178","author":"KT Choy","year":"2020","unstructured":"Choy, K. T. et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antivir. Res. 178, 104786 (2020).","journal-title":"Antivir. Res"},{"key":"561_CR42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40487-018-0058-6","volume":"6","author":"ES Winer","year":"2018","unstructured":"Winer, E. S. & DeAngelo, D. J. A review of omacetaxine: a chronic myeloid leukemia treatment resurrected. Oncol. Ther. 6, 9\u201320 (2018).","journal-title":"Oncol. Ther."},{"key":"561_CR43","doi-asserted-by":"publisher","first-page":"12502","DOI":"10.1093\/nar\/gkaa1116","volume":"48","author":"S de Breyne","year":"2020","unstructured":"de Breyne, S. et al. Translational control of coronaviruses. Nucleic Acids Res. 48, 12502\u201312522 (2020).","journal-title":"Nucleic Acids Res."},{"key":"561_CR44","unstructured":"ClinicalTrials.gov. US National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04461340."},{"key":"561_CR45","unstructured":"ClinicalTrials.gov. US National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04584710."},{"key":"561_CR46","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.3390\/cells9051267","volume":"9","author":"M Romano","year":"2020","unstructured":"Romano, M., Ruggiero, A., Squeglia, F., Maga, G. & Berisio, R. A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping. Cells 9, 1267 (2020).","journal-title":"Cells"},{"key":"561_CR47","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.abf4058","volume":"371","author":"KM White","year":"2021","unstructured":"White, K. M. et al. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science 371, 926\u2013931 (2021).","journal-title":"Science"},{"key":"561_CR48","doi-asserted-by":"publisher","first-page":"e202101200","DOI":"10.26508\/lsa.202101200","volume":"5","author":"JF Varona","year":"2022","unstructured":"Varona, J. F. et al. Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19. Life Sci. Alliance 5, e202101200 (2022).","journal-title":"Life Sci. Alliance"},{"key":"561_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15562-9","volume":"11","author":"X Ou","year":"2020","unstructured":"Ou, X. et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 11, 1620 (2020).","journal-title":"Nat. Commun."},{"key":"561_CR50","doi-asserted-by":"publisher","first-page":"7108","DOI":"10.1093\/emboj\/20.24.7108","volume":"20","author":"O Kassel","year":"2001","unstructured":"Kassel, O. et al. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J. 20, 7108\u20137116 (2001).","journal-title":"EMBO J."},{"key":"561_CR51","doi-asserted-by":"publisher","first-page":"9279","DOI":"10.1128\/JVI.00659-06","volume":"80","author":"C-P Chan","year":"2006","unstructured":"Chan, C.-P. et al. Modulation of the unfolded protein response by the severe acute respiratory syndrome coronavirus spike protein. J. Virol. 80, 9279\u20139287 (2006).","journal-title":"J. Virol."},{"key":"561_CR52","doi-asserted-by":"publisher","first-page":"10981","DOI":"10.1128\/JVI.01033-07","volume":"81","author":"GA Versteeg","year":"2007","unstructured":"Versteeg, G. A., van de Nes, P. S., Bredenbeek, P. J. & Spaan, W. J. M. The coronavirus spike protein induces endoplasmic reticulum stress and upregulation of intracellular chemokine mRNA concentrations. J. Virol. 81, 10981\u201310990 (2007).","journal-title":"J. Virol."},{"key":"561_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmicb.2014.00296","volume":"5","author":"TS Fung","year":"2014","unstructured":"Fung, T. S. & Liu, D. X. Coronavirus infection, ER stress, apoptosis and innate immunity. Front. Microbiol. 5, 1\u201313 (2014).","journal-title":"Front. Microbiol."},{"key":"561_CR54","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1146\/annurev-micro-020518-115759","volume":"73","author":"TS Fung","year":"2019","unstructured":"Fung, T. S. & Liu, D. X. Human coronavirus: host-pathogen interaction. Annu. Rev. Microbiol. 73, 529\u2013557 (2019).","journal-title":"Annu. Rev. Microbiol."},{"key":"561_CR55","doi-asserted-by":"publisher","unstructured":"Hsu, A. C.-Y. et al. SARS-CoV-2 Spike protein promotes hyper-inflammatory response that can be ameliorated by Spike-antagonistic peptide and FDA-approved ER stress and MAP kinase inhibitors in vitro. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.09.30.317818 (2020).","DOI":"10.1101\/2020.09.30.317818"},{"key":"561_CR56","doi-asserted-by":"publisher","unstructured":"Zhang, X. et al. Sequential ER stress and inflammatory responses are induced by SARS-CoV-2 ORF3 through ERphagy. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.11.17.387902 (2020).","DOI":"10.1101\/2020.11.17.387902"},{"key":"561_CR57","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.biocel.2015.01.015","volume":"61","author":"PS Kolb","year":"2015","unstructured":"Kolb, P. S. et al. The therapeutic effects of 4-phenylbutyric acid in maintaining proteostasis. Int. J. Biochem. Cell Biol. 61, 45\u201352 (2015).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"561_CR58","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2165\/11591280-000000000-00000","volume":"11","author":"T Iannitti","year":"2011","unstructured":"Iannitti, T. & Palmieri, B. Clinical and experimental applications of sodium phenylbutyrate. Drugs R. D. 11, 227\u2013249 (2011).","journal-title":"Drugs R. D."},{"key":"561_CR59","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(20)32013-4","volume":"396","author":"PW Horby","year":"2020","unstructured":"Horby, P. W. et al. Lopinavir\u2013ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 396, 1345\u20131352 (2020).","journal-title":"Lancet"},{"key":"561_CR60","doi-asserted-by":"publisher","first-page":"10012","DOI":"10.1073\/pnas.0403596101","volume":"101","author":"CY Wu","year":"2004","unstructured":"Wu, C. Y. et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc. Natl Acad. Sci. USA 101, 10012\u201310017 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"561_CR61","doi-asserted-by":"publisher","unstructured":"Jang, M. et al. Lopinavir-ritonavir is not an effective inhibitor of the main protease activity of SARS-CoV-2 in vitro. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.09.16.299800 (2020).","DOI":"10.1101\/2020.09.16.299800"},{"key":"561_CR62","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1126\/science.abf1611","volume":"371","author":"J Qiao","year":"2021","unstructured":"Qiao, J. et al. SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model. Science 371, 1374\u20131378 (2021).","journal-title":"Science"},{"key":"561_CR63","unstructured":"ClinicalTrials.gov. US National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04960202 (2021)."},{"key":"561_CR64","unstructured":"ClinicalTrials.gov. US National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04499677 (2020)."},{"key":"561_CR65","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.medj.2020.07.002","volume":"2","author":"J Li","year":"2021","unstructured":"Li, J. et al. Virus-host interactome and proteomic survey reveal potential virulence factors influencing SARS-CoV-2 pathogenesis. Med 2, 99\u2013112.e7 (2021).","journal-title":"Med"},{"key":"561_CR66","doi-asserted-by":"publisher","first-page":"102763","DOI":"10.1016\/j.ebiom.2020.102763","volume":"55","author":"J Liu","year":"2020","unstructured":"Liu, J. et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 55, 102763 (2020).","journal-title":"EBioMedicine"},{"key":"561_CR67","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/imm.13223","volume":"160","author":"M Tan","year":"2020","unstructured":"Tan, M. et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Immunology 160, 261\u2013268 (2020).","journal-title":"Immunology"},{"key":"561_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/embj.2020105896","volume":"39","author":"Y Chen","year":"2020","unstructured":"Chen, Y. et al. Blood molecular markers associated with COVID\u201019 immunopathology and multi\u2010organ damage. EMBO J. 39, 1\u201323 (2020).","journal-title":"EMBO J."},{"key":"561_CR69","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","volume":"26","author":"DM Del Valle","year":"2020","unstructured":"Del Valle, D. M. et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 26, 1636\u20131643 (2020).","journal-title":"Nat. Med."},{"key":"561_CR70","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280.e8 (2020).","journal-title":"Cell"},{"key":"561_CR71","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1128\/AAC.03659-14","volume":"59","author":"J Kindrachuk","year":"2015","unstructured":"Kindrachuk, J. et al. Antiviral potential of ERK\/MAPK and PI3K\/AKT\/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob. Agents Chemother. 59, 1088\u20131099 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"561_CR72","doi-asserted-by":"publisher","first-page":"108940","DOI":"10.1016\/j.celrep.2021.108940","volume":"35","author":"G Garcia","year":"2021","unstructured":"Garcia, G. et al. Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication. Cell Rep. 35, 108940 (2021).","journal-title":"Cell Rep"},{"key":"561_CR73","doi-asserted-by":"publisher","first-page":"108959","DOI":"10.1016\/j.celrep.2021.108959","volume":"35","author":"M Dittmar","year":"2021","unstructured":"Dittmar, M. et al. Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2. Cell Rep. 35, 108959 (2021).","journal-title":"Cell Rep."},{"key":"561_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23328-0","volume":"12","author":"MA Bakowski","year":"2021","unstructured":"Bakowski, M. A. et al. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. Nat. Commun. 12, 3309 (2021).","journal-title":"Nat. Commun."},{"key":"561_CR75","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","volume":"10","author":"C Wu","year":"2020","unstructured":"Wu, C. et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm. Sin. B 10, 766\u2013788 (2020).","journal-title":"Acta Pharm. Sin. B"},{"key":"561_CR76","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","volume":"583","author":"DE Gordon","year":"2020","unstructured":"Gordon, D. E. et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583, 459\u2013468 (2020).","journal-title":"Nature"},{"key":"561_CR77","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.cell.2020.06.034","volume":"182","author":"M Bouhaddou","year":"2020","unstructured":"Bouhaddou, M. et al. The global phosphorylation landscape of SARS-CoV-2 infection. Cell 182, 685\u2013712.e19 (2020).","journal-title":"Cell"},{"key":"561_CR78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41597-019-0340-y","volume":"7","author":"M Ostaszewski","year":"2020","unstructured":"Ostaszewski, M. et al. COVID-19 disease map, building a computational repository of SARS-CoV-2 virus-host interaction mechanisms. Sci. Data 7, 1\u201357 (2020).","journal-title":"Sci. Data"},{"key":"561_CR79","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1089\/nsm.2020.0011","volume":"3","author":"N Verstraete","year":"2020","unstructured":"Verstraete, N. et al. CovMulNet19, integrating proteins, diseases, drugs, and symptoms: a network medicine approach to COVID-19. Netw. Syst. Med. 3, 130\u2013141 (2020).","journal-title":"Netw. Syst. Med"},{"key":"561_CR80","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","volume":"395","author":"P Richardson","year":"2020","unstructured":"Richardson, P. et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 395, e30\u2013e31 (2020).","journal-title":"Lancet"},{"key":"561_CR81","doi-asserted-by":"publisher","first-page":"e1009753","DOI":"10.1371\/journal.ppat.1009753","volume":"17","author":"AL Jenner","year":"2021","unstructured":"Jenner, A. L. et al. COVID-19 virtual patient cohort suggests immune mechanisms driving disease outcomes. PLOS Pathog. 17, e1009753 (2021).","journal-title":"PLOS Pathog."},{"key":"561_CR82","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1021\/acsptsci.0c00183","volume":"4","author":"P Dogra","year":"2021","unstructured":"Dogra, P. et al. Innate immunity plays a key role in controlling viral load in COVID-19: mechanistic insights from a whole-body infection dynamics model. ACS Pharmacol. Transl. Sci. 4, 248\u2013265 (2021).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"561_CR83","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/nbt1356","volume":"25","author":"J Fisher","year":"2007","unstructured":"Fisher, J. & Henzinger, T. A. Executable cell biology. Nat. Biotechnol. 25, 1239\u20131249 (2007).","journal-title":"Nat. Biotechnol."},{"key":"561_CR84","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-021-01355-0","volume":"27","author":"C Lucas","year":"2021","unstructured":"Lucas, C. et al. Delayed production of neutralizing antibodies correlates with fatal COVID-19. Nat. Med. 27, 1178\u20131186 (2021).","journal-title":"Nat. Med."},{"key":"561_CR85","doi-asserted-by":"publisher","first-page":"e041276","DOI":"10.1136\/bmjopen-2020-041276","volume":"10","author":"CW Jones","year":"2020","unstructured":"Jones, C. W., Woodford, A. L. & Platts-Mills, T. F. Characteristics of COVID-19 clinical trials registered with ClinicalTrials.gov: cross-sectional analysis. BMJ Open 10, e041276 (2020).","journal-title":"BMJ Open"},{"key":"561_CR86","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.cmi.2020.05.019","volume":"26","author":"PC Fragkou","year":"2020","unstructured":"Fragkou, P. C. et al. Review of trials currently testing treatment and prevention of COVID-19. Clin. Microbiol. Infect. 26, 988\u2013998 (2020).","journal-title":"Clin. Microbiol. Infect."},{"key":"561_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-77748-x","volume":"10","author":"RM Ghazy","year":"2020","unstructured":"Ghazy, R. M. et al. A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment. Sci. Rep. 10, 22139 (2020).","journal-title":"Sci. Rep."},{"key":"561_CR88","doi-asserted-by":"publisher","first-page":"114296","DOI":"10.1016\/j.bcp.2020.114296","volume":"183","author":"H Yousefi","year":"2021","unstructured":"Yousefi, H., Mashouri, L., Okpechi, S. C., Alahari, N. & Alahari, S. K. Repurposing existing drugs for the treatment of COVID-19\/SARS-CoV-2 infection: A review describing drug mechanisms of action. Biochem. Pharmacol. 183, 114296 (2021).","journal-title":"Biochem. Pharmacol."},{"key":"561_CR89","doi-asserted-by":"publisher","unstructured":"Jackson, C. B., Farzan, M., Chen, B. & Choe, H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. https:\/\/doi.org\/10.1038\/s41580-021-00418-x (2021).","DOI":"10.1038\/s41580-021-00418-x"},{"key":"561_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21118-2","volume":"12","author":"S Ozono","year":"2021","unstructured":"Ozono, S. et al. SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity. Nat. Commun. 12, 848 (2021).","journal-title":"Nat. Commun."},{"key":"561_CR91","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1098\/rsif.2008.0132.focus","volume":"5","author":"S Bornholdt","year":"2008","unstructured":"Bornholdt, S. Boolean network models of cellular regulation: prospects and limitations. J. R. Soc. Interface 5, S85\u201394 (2008).","journal-title":"J. R. Soc. Interface"},{"key":"561_CR92","doi-asserted-by":"crossref","unstructured":"Benque, D. et al. BMA: visual tool for modeling and analyzing biological networks. Comput. Aided Verif. 686\u2013692 (2012).","DOI":"10.1007\/978-3-642-31424-7_50"},{"key":"561_CR93","first-page":"134","volume":"6538 LNCS","author":"B Cook","year":"2011","unstructured":"Cook, B., Fisher, J., Krepska, E. & Piterman, N. Proving stabilization of biological systems. Lect. Notes Comput. Sci. (including Subser. Lect. Notes Artif. Intell. Lect. Notes Bioinforma.) 6538 LNCS, 134\u2013149 (2011).","journal-title":"Lect. Notes Comput. Sci. (including Subser. Lect. Notes Artif. Intell. Lect. Notes Bioinforma.)"},{"key":"561_CR94","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/nar\/gkj067","volume":"34","author":"DS Wishart","year":"2006","unstructured":"Wishart, D. S. et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34, 668\u2013672 (2006).","journal-title":"Nucleic Acids Res"},{"key":"561_CR95","doi-asserted-by":"publisher","first-page":"e00149","DOI":"10.1002\/prp2.149","volume":"3","author":"J Foucquier","year":"2015","unstructured":"Foucquier, J. & Guedj, M. Analysis of drug combinations: current methodological landscape. Pharmacol. Res. Perspect. 3, e00149 (2015).","journal-title":"Pharmacol. Res. Perspect"},{"key":"561_CR96","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","volume":"26","author":"CI Bliss","year":"1939","unstructured":"Bliss, C. I. The toxicity of poisons applied jointly. Ann. Appl. Biol. 26, 585\u2013615 (1939).","journal-title":"Ann. Appl. Biol."},{"key":"561_CR97","unstructured":"R Core Team. R: a language and environment for statistical computing. (2017)."},{"key":"561_CR98","unstructured":"Kolde, R. pheatmap: pretty heatmaps. (2015)."},{"key":"561_CR99","unstructured":"Nakazawa, M. fmsb: functions for medical statistics book with some demographic data. (2021)."},{"key":"561_CR100","unstructured":"Neuwirth, E. RColorBrewer: ColorBrewer palettes. (2014)."},{"key":"561_CR101","unstructured":"Yu, G. ggplotify: convert plot to \u2018grob\u2019 or \u2018ggplot\u2019 object. (2021)."},{"key":"561_CR102","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham, H. et al. Welcome to the Tidyverse. J. Open Source Softw. 4, 1686 (2019).","journal-title":"J. Open Source Softw"}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-022-00561-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-022-00561-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-022-00561-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T03:23:29Z","timestamp":1669346609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-022-00561-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":102,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["561"],"URL":"https:\/\/doi.org\/10.1038\/s41746-022-00561-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.07.27.453973","asserted-by":"object"}]},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]},"assertion":[{"value":"29 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}